D F Florescu

Summary

Affiliation: University of Nebraska Medical Center
Country: USA

Publications

  1. Florescu D, Pergam S, Neely M, Qiu F, Johnston C, Way S, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012;18:731-8 pubmed publisher
    ..5 days; P = .04). No serious adverse events were attributed to CMX001 during therapy. CMX001 may be a promising therapeutic option for the treatment of severe adenovirus disease in immunocompromised patients. ..
  2. Florescu D, Kwon J, Dumitru I. Adenovirus infections in heart transplantation. Cardiol Rev. 2013;21:203-6 pubmed publisher
    ..Cidofovir is currently considered the standard of treatment for adenovirus disease not responding to reduction of immunosuppression. ..
  3. Florescu D, Mindru C, Keck M, Qiu F, Kalil A. Colistin, an Old Drug in a New Territory, Solid Organ Transplantation. Transplant Proc. 2016;48:152-7 pubmed publisher
    ..One patient had both neurotoxicity and nephrotoxicity, and 1 patient had neurotoxicity only. Colistin might be used as an alternate therapy for transplant patients with multidrug-resistant Gram-negative pathogens. ..
  4. Poole J, Qiu F, Kalil A, Grant W, Mercer D, Florescu D. Impact of Immunoglobulin Therapy in Intestinal Transplant Recipients With Posttransplantation Hypogammaglobulinemia. Transplant Proc. 2016;48:479-84 pubmed publisher
    ..10). Improved survival rates were not found in our IT recipients with severe HGG with immunoglobulin therapy to IgG levels of ?400 mg/dL, even when cytomegalovirus hyperimmunoglobulin was administered. ..
  5. Florescu D, Hill L, Sudan D, Iwen P. Leuconostoc bacteremia in pediatric patients with short bowel syndrome: case series and review. Pediatr Infect Dis J. 2008;27:1013-9 pubmed publisher
    ..This article presents 6 new cases of pediatric patients with short bowel syndrome who developed Leuconostoc bacteremia, and compares these cases with those previously reported in the literature...
  6. Florescu D, Islam K, Grant W, Mercer D, Langnas A, Botha J, et al. Incidence and outcome of fungal infections in pediatric small bowel transplant recipients. Transpl Infect Dis. 2010;12:497-504 pubmed publisher
    ..12, 95% CI 0.45, 2.8). Fungal infections occurred in 25% of SBT recipients and C. albicans was the most common species. Intra-abdominal fungal infections occurred earlier (<1 month) than fungemia (>6 months) post transplantation. ..
  7. Florescu D, Hermsen E, Kwon J, Gumeel D, Grant W, Mercer D, et al. Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients?. Pediatr Transplant. 2011;15:718-21 pubmed publisher
    ..32, OR = 1.0). We show a potential role of OHIG treatment for NVE. Resolution of diarrhea and decreased stool output were observed at seven days; no benefit was found for length of hospital stay or hospital cost. ..
  8. Florescu D, Qiu F, McCartan M, Mindru C, Fey P, Kalil A. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012;54:670-80 pubmed publisher
    ..Our results suggest that colistin may be as safe and as efficacious as standard antibiotics for the treatment of VAP. ..
  9. Florescu D, Langnas A, Sandkovsky U. Opportunistic viral infections in intestinal transplantation. Expert Rev Anti Infect Ther. 2013;11:367-81 pubmed publisher
    ..5, 58.2 and 47%, respectively. IT restores organ functions, but it is associated with complications, with infections representing the major cause of morbidity and mortality in this population. ..